To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease ...

Narrows FY24 total operating expenses view to $365M-$370M from $355M-$375M, which includes milestone payments that the Company expects to ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

The Company announced a $350 million royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo. Under the agreement, Syndax received $350 million in exchange for a 13.8% ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Royalty Pharma (NASDAQ:RPRX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect Royalty Pharma to post ...

Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, Marketbeat.com reports. One ...

Citi lowered the firm’s price target on Royalty Pharma (RPRX) to $40 from $60 and keeps a Buy rating on the shares following a transfer of coverage. Royalties from Vertex’s portfolio of assets ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Royalty Pharma plc (RPRX) current and estimated P/E ratio data provided by Seeking Alpha.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...